Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in New-onset Juvenile Dermatomyositis
NCT05524311Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2022
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in juvenile dermatomyositis (JDM), sponsored by Assistance publique - Hôpitaux de Paris. Started Nov 2022; status: completed.
02
Drugs
baricitinib
03
Conditions
juvenile dermatomyositis (JDM)
Beyond the preview
Go deeper on NCT05524311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524311.